Top Markets
Coin of the day
Eikon Therapeutics, Inc. Common Stock Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock

EIKN
Rank in Stocks #12325
Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established... Eikon Therapeutics, Inc. is a clinical biopharmaceutical company, established in 2019 and headquartered in Millbrae, California, operating within the United States. The company is dedicated to developing groundbreaking medicines to address significant unmet medical needs. It utilizes a proprietary platform capable of precisely characterizing protein interactions inside living cells. Eikon's drug pipeline includes EIK1001, a systemically delivered TLR 7/8 dual-agonist designed to activate both innate and adaptive anti-cancer immune responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors for ovarian, breast, prostate, and pancreatic cancers. Notably, EIK1004 is brain-penetrant, offering a therapeutic approach for brain metastases and primary brain malignancies. Additionally, EIK1005 is a potent WRN helicase inhibitor and anti-tumor agent aimed at MSI-high tumors, alongside EIK1006.
Share Price
$11.03
Last synced: 2026-08-28
Market Cap
$597.15M
Change (1 day)
-4.25%
Change (1 year)
-
Country
US
Trade Eikon Therapeutics, Inc. Common Stock (EIKN)

Category

EPS for Eikon Therapeutics, Inc. Common Stock (EIKN)
EPS as of 2026 TTM: 0
According to Eikon Therapeutics, Inc. Common Stock latest financial reports and stock price the company's current EPS (TTM) is 0. At the end of 2026 the company had a EPS of 0 equal to its 2026 EPS that were of 0.
EPS history for Eikon Therapeutics, Inc. Common Stock from 2026 to 2026
EPS at the end of each year
Year EPS Change
Not enough data for the provided dates.
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -
US
$27.74 -
NL
$-5.29 -
AU
$-7.98 -
US
- -
CH